Workflow
股票收益
icon
Search documents
Caterpillar Stock on a Record Run Ahead of Earnings
Schaeffers Investment Research· 2025-07-31 17:16
Core Viewpoint - Caterpillar Inc is set to report its second-quarter earnings, with expectations of a decline in earnings per share but an increase in revenue [1] Group 1: Earnings Expectations - Wall Street anticipates earnings of $4.88 per share, representing an 18.5% decline from the same quarter last year [1] - Revenue is expected to reach $16.35 billion, indicating a 2% year-over-year increase [1] Group 2: Stock Performance - Caterpillar's stock has reached an all-time high of $439.95, continuing a trend of record highs [2] - The stock has increased approximately 13% in July, marking its third consecutive month of double-digit percentage gains [2] - Year-to-date, the stock has risen by 21% [2] Group 3: Post-Earnings History - Historically, Caterpillar's stock has shown mixed results post-earnings, finishing four of the last eight sessions higher and four lower [4] - Options traders are anticipating an earnings swing of 4.9%, slightly above the average of 4.4% over the past two years [4] Group 4: Options Activity - There has been a notable increase in call options activity, with a 50-day call/put volume ratio of 1.89, ranking higher than 98% of readings from the past year [5]
Sell AbbVie Stock Ahead of Its Upcoming Earnings?
Forbes· 2025-07-30 13:30
Core Insights - AbbVie is set to release its earnings report on July 31, 2025, with current consensus estimates projecting earnings of $2.91 per share on sales of $15.03 billion, compared to $2.65 per share on sales of $14.46 billion in the same quarter last year [3][4] Historical Performance - Over the past five years, AbbVie has experienced a negative one-day return following earnings announcements in 65% of instances, with a median decline of -1.3% and a maximum drop of -7.3% [3][7] - There have been 20 earnings data points recorded over the last five years, with 7 positive and 13 negative one-day returns, resulting in positive returns approximately 35% of the time; this percentage decreases to 17% when considering the last 3 years [7] Financial Metrics - AbbVie currently has a market capitalization of $333 billion, with $57 billion in revenue, $13 billion in operating profits, and a net income of $4.2 billion over the last twelve months [4] Trading Strategies - Traders can analyze historical probabilities and take positions before earnings releases, as well as examine correlations between immediate and medium-term returns post-earnings to adjust positions accordingly [6][8]